ACADIA Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ACADIA Pharmaceuticals (ACAD).

Price Target Range — 10 Quarters

Analyst Consensus — 21 Analysts

2S.Buy

15Buy

3Hold

1Sell

Consensus RatingBuy# Analysts21Avg. Consensus PT$32Upside to Avg. PT+9.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 25, 2026	Deutsche Bank	David Hoang	PT Raise	Buy	$37→$38
Aug 25, 2026	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$27→$28
Aug 25, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$39→$40
Aug 17, 2026	UBS	Ashwani Verma	PT Raise	Buy	$45→$49
Aug 12, 2026	Needham	Ami Fadia	PT Raise	Buy	$38→$41
Aug 10, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$35→$39
Aug 5, 2026	Oppenheimer	Matthew Hershenhorn	PT Raise	Perform	$23→$25
Aug 5, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$36→$37
Aug 5, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$35→$36
Jul 21, 2026	Stifel	Paul Matteis	PT Raise	Hold	$24→$25
Jul 21, 2026	BMO Capital	Evan David Seigerman	PT Raise	Outperform	$34→$36
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$29→$36
Jun 30, 2026	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$29→$30
Jun 29, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$32→$35
Jun 29, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$32→$36
May 8, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$33→$32
May 7, 2026	Canaccord Genuity	Sumant Kulkarni	PT Cut	Buy	$33→$32
Mar 25, 2026	B of A Securities	Tazeen Ahmad	Upgrade	Neutral→Buy	$29
Mar 4, 2026	JP Morgan	Tessa Romero	PT Raise	Overweight	$31→$34
Feb 27, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$31→$33

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38

Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28

Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $27 to $28.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $39 to $40.

Benzinga Newsdesk

PRO
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49

UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $45 to $49.

Benzinga Newsdesk

PRO
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $38 to $41.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 to $39.

Benzinga Newsdesk

ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38

PRO
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28

PRO
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40

PRO
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49

PRO
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41

PRO
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39

People Also Watch

People Also Watch

Benzinga

Benzinga

ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRODeutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38

PROMorgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28

PROCitigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40

PROUBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49

PRONeedham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41

PROCitigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39

People Also Watch

People Also Watch

PRO
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38

PRO
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28

PRO
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40

PRO
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49

PRO
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41

PRO
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39